Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Molecular and Cellular Biochemistry Year : 2022

Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression

Abstract

Abstract Diabetes mellitus (DM)-induced cardiac morbidities have been the leading cause of death among diabetic patients. Recently, sodium-glucose cotransporter-2 (SGLT-2) inhibitors including empagliflozin (EMPA), which have been approved for the treatment of DM, have gained attention for their cardioprotective effect. The mechanism by which SGLT-2 inhibitors exert their cardioprotective effect remains unclear. Recent studies have suggested that EMPA exerts its cardioprotective effect by inhibiting the Na + /H + exchanger (NHE), a group of membrane proteins that regulate intracellular pH and cell volume. Increased activity and expression of NHE isoform 1 (NHE1), the predominant isoform expressed in the heart, leads to cardiac hypertrophy. p90 ribosomal s6 kinase (p90 RSK) has been demonstrated to stimulate NHE1 activity. In our study, H9c2 cardiomyoblasts were treated with angiotensin II (ANG) to activate NHE1 and generate a hypertrophic model. We aimed to understand whether EMPA reverses the ANG-induced hypertrophic response and to elucidate the molecular pathway contributing to the cardioprotective effect of EMPA. Our study demonstrated that ANG-induced hypertrophy of H9c2 cardiomyoblasts is accompanied with increased SGLT-1 and NHE1 protein expression, an effect which is prevented in the presence of EMPA. EMPA reduces ANG-induced hypertrophy through the inhibition of SGLT-1 and NHE1 expression.
Fichier principal
Vignette du fichier
Abdulrahman2022_Article_EmpagliflozinInhibitsAngiotens.pdf (890.92 Ko) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

inserm-03627256 , version 1 (01-04-2022)

Identifiers

Cite

Nabeel Abdulrahman, Meram Ibrahim, Jensa Mariam Joseph, Hanan Mahmoud Elkoubatry, Al-Anood Al-Shamasi, et al.. Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression. Molecular and Cellular Biochemistry, 2022, Online ahead of print. ⟨10.1007/s11010-022-04411-6⟩. ⟨inserm-03627256⟩

Collections

INSERM CNRS U1034
32 View
22 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More